Shuli Xia1, Bachchu Lal1, Brian Tung1, Shervin Wang1, C Rory Goodwin1, John Laterra1. 1. Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland (S.X., B.L., B.T., S.W., C.R.G., J.L.); Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland (S.X., B.L., C.R.G., J.L.); Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland (C.R.G., J.L.); Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland (J.L.).
Abstract
BACKGROUND: Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults. Recent research on cancer stroma indicates that the brain microenvironment plays a substantial role in tumor malignancy and treatment responses to current antitumor therapy. In this work, we have investigated the effect of alterations in brain tumor extracellular matrix tenascin-C (TNC) on brain tumor growth patterns including proliferation and invasion. METHODS: Since intracranial xenografts from patient-derived GBM neurospheres form highly invasive tumors that recapitulate the invasive features demonstrated in human patients diagnosed with GBM, we studied TNC gain-of-function and loss-of function in these GBM neurospheres in vitro and in vivo. RESULTS: TNC loss-of-function promoted GBM neurosphere cell adhesion and actin cytoskeleton organization. Yet, TNC loss-of-function or exogenous TNC had no effect on GBM neurosphere cell growth in vitro. In animal models, decreased TNC in the tumor microenvironment was accompanied by decreased tumor invasion and increased tumor proliferation, suggesting that TNC regulates the "go-or-grow" phenotypic switch of glioma in vivo. We demonstrated that decreased TNC in the tumor microenvironment modulated behaviors of stromal cells including endothelial cells and microglia, resulting in enlarged tumor blood vessels and activated microglia in tumors. We further demonstrated that tumor cells with decreased TNC expression are sensitive to anti-proliferative treatment in vitro. CONCLUSION: Our findings suggest that detailed understanding of how TNC in the tumor microenvironment influences tumor behavior and the interactions between tumor cells and surrounding nontumor cells will benefit novel combinatory antitumor strategies to treat malignant brain tumors.
BACKGROUND:Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults. Recent research on cancer stroma indicates that the brain microenvironment plays a substantial role in tumor malignancy and treatment responses to current antitumor therapy. In this work, we have investigated the effect of alterations in brain tumor extracellular matrix tenascin-C (TNC) on brain tumor growth patterns including proliferation and invasion. METHODS: Since intracranial xenografts from patient-derived GBM neurospheres form highly invasive tumors that recapitulate the invasive features demonstrated in humanpatients diagnosed with GBM, we studied TNC gain-of-function and loss-of function in these GBM neurospheres in vitro and in vivo. RESULTS:TNC loss-of-function promoted GBM neurosphere cell adhesion and actin cytoskeleton organization. Yet, TNC loss-of-function or exogenous TNC had no effect on GBM neurosphere cell growth in vitro. In animal models, decreased TNC in the tumor microenvironment was accompanied by decreased tumor invasion and increased tumor proliferation, suggesting that TNC regulates the "go-or-grow" phenotypic switch of glioma in vivo. We demonstrated that decreased TNC in the tumor microenvironment modulated behaviors of stromal cells including endothelial cells and microglia, resulting in enlarged tumor blood vessels and activated microglia in tumors. We further demonstrated that tumor cells with decreased TNC expression are sensitive to anti-proliferative treatment in vitro. CONCLUSION: Our findings suggest that detailed understanding of how TNC in the tumor microenvironment influences tumor behavior and the interactions between tumor cells and surrounding nontumor cells will benefit novel combinatory antitumor strategies to treat malignant brain tumors.
Authors: Justin D Lathia; Joseph Gallagher; John M Heddleston; Jialiang Wang; Christine E Eyler; Jennifer Macswords; Qiulian Wu; Amit Vasanji; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich Journal: Cell Stem Cell Date: 2010-05-07 Impact factor: 24.633
Authors: Kim Midwood; Sandra Sacre; Anna M Piccinini; Julia Inglis; Annette Trebaul; Emma Chan; Stefan Drexler; Nidhi Sofat; Masahide Kashiwagi; Gertraud Orend; Fionula Brennan; Brian Foxwell Journal: Nat Med Date: 2009-06-28 Impact factor: 53.440
Authors: Thordur Oskarsson; Swarnali Acharyya; Xiang H-F Zhang; Sakari Vanharanta; Sohail F Tavazoie; Patrick G Morris; Robert J Downey; Katia Manova-Todorova; Edi Brogi; Joan Massagué Journal: Nat Med Date: 2011-06-26 Impact factor: 53.440
Authors: Bachchu Lal; C Rory Goodwin; Yingying Sang; Catherine A Foss; Kathrine Cornet; Sameena Muzamil; Martin G Pomper; Jin Kim; John Laterra Journal: Mol Cancer Ther Date: 2009-07-07 Impact factor: 6.261
Authors: Peng Sun; Shuli Xia; Bachchu Lal; Charles G Eberhart; Alfredo Quinones-Hinojosa; Jarek Maciaczyk; William Matsui; Francesco Dimeco; Sara M Piccirillo; Angelo L Vescovi; John Laterra Journal: Stem Cells Date: 2009-07 Impact factor: 6.277
Authors: Shilpa Bhatia; Sanjana Bukkapatnam; Benjamin Van Court; Andy Phan; Ayman Oweida; Jacob Gadwa; Adam C Mueller; Miles Piper; Laurel Darragh; Diemmy Nguyen; Ahmed Gilani; Michael Knitz; Thomas Bickett; Adam Green; Sujatha Venkataraman; Rajeev Vibhakar; Diana Cittelly; Sana D Karam Journal: Mol Carcinog Date: 2020-06-22 Impact factor: 4.784
Authors: Dongsic Choi; Laura Montermini; Dae-Kyum Kim; Brian Meehan; Frederick P Roth; Janusz Rak Journal: Mol Cell Proteomics Date: 2018-07-13 Impact factor: 5.911
Authors: Heather M Brechbuhl; Alexander S Barrett; Etana Kopin; Jaime C Hagen; Amy L Han; Austin E Gillen; Jessica Finlay-Schultz; Diana M Cittelly; Philip Owens; Kathryn B Horwitz; Carol A Sartorius; Kirk Hansen; Peter Kabos Journal: JCI Insight Date: 2020-02-27